4-(2-Oxo-1,2-dihydro-quinolin-6-yloxy)-butyramide | 87364-50-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: 4-(2-Oxo-1,2-dihydro-quinolin-6-yloxy)-butyramide
• 英文别名: 4-[(2-oxo-1H-quinolin-6-yl)oxy]butanamide
• CAS: 87364-50-9
• 化学式: C₁₃H₁₄N₂O₃
• 分子量: 246.266
• InChiKey: RYGXCXILSVRFOH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.23
• 拓扑面积：
  81.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-[(2-氧代-1H-喹啉-6-基)氧基]丁酸 在 氨 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 氯甲酸异丁酯 作用下， 生成 4-(2-Oxo-1,2-dihydro-quinolin-6-yloxy)-butyramide
  参考文献：
  名称：

  Studies on 2-oxoquinoline derivatives as blood platelet aggregation inhibitors. III. N-Cyclohexyl-N-(2-hydroxyethyl)-4-(1,2-dihydro-2-oxo-6-quinolyloxy)butyramide and related compounds.

  摘要：

  合成了一系列 N,N-取代的ω-(1, 2-二氢-2-氧羟喹啉氧基)烷基氨基酸酰胺，并对其在体外对胶原和ADP诱导的兔血小板聚集的抑制活性进行了测试。这些化合物是通过ω-(1, 2-二氢-2-氧羟喹啉氧基)烷酸与各种胺反应，采用混合酸酐法制备的。其中，N-环己基-N-(2-羟乙基)-4-(1, 2-二氢-2-氧-6-喹啉氧基)丁酰胺（IVa1）被发现具有最强的抑制活性。文中讨论了结构-活性关系。

  DOI：

  10.1248/cpb.31.852

文献信息

• NISHI, TAKAO;TABUSA, FUJIO;TANAKA, TATSUYOSHI;UEDA, HIRAKI;SHIMIZU, TAKEF+, CHEM. AND PHARM. BULL., 1983, 31, N 3, 852-860
  作者：NISHI, TAKAO、TABUSA, FUJIO、TANAKA, TATSUYOSHI、UEDA, HIRAKI、SHIMIZU, TAKEF+

  DOI：——

  日期：——
• METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS
  申请人：Exxonmobil Research And Engineering Company

  公开号：EP3237903A1

  公开（公告）日：2017-11-01
• [EN] METHODS FOR AUTHENTICATION AND IDENTIFICATION OF PETROLEUM PRODUCTS<br/>[FR] PROCÉDÉS D'AUTHENTIFICATION ET D'IDENTIFICATION DE PRODUITS PÉTROLIERS
  申请人：EXXONMOBIL RES & ENG CO

  公开号：WO2016106211A1

  公开（公告）日：2016-06-30

  A method is provided that associates a taggant with a product to produce a signature product. The taggant, when associated with the signature product, is visually undetectable; and comprises one or more amide compounds (e.g., a taggant array that comprises two or more amide compounds). The method also identifies the taggant in the signature product by an immunoassay specific for the taggant; maps the taggant of the signature product to a batch code of the signature product; obtains a test product to determine authenticity or identity of the test product; identifies the presence or absence of a taggant in the test product by an immunoassay specific for the taggant; and compares results of the immunoassay carried out on the test product with results of the immunoassay carried out on the signature product to determine authenticity or identity of the test product. Lubricating engine oils are provided containing the taggant.